Danish biotechnology firm Genmab has unveiled positive results from a Phase II study of its sclerosis drug candidate ofatumumab in relapsing-remitting multiple sclerosis (RRMS). In a randomized study of 232 patients with RRMS, treatment ...
Tags: Genmab, Sclerosis Drug
US-based drug discovery and development firm, Heptares Therapeutics has delivered the first stabilised G protein-coupled receptor (GPCR) called 'StaR' to MorphoSys for antibody discovery as part of their antibody therapeutics alliance. ...
Tags: Heptares Therapeutics, drug
NovaDigm Therapeutics has started a Phase Ib/IIa clinical trial of its NDV-3 vaccine, which is being developed to prevent episodes of vulvovaginal candidiasis (VVC) in patients with recurrent VVC (RVVC). Under the trial, which is a ...
Tags: NDV-3 Vaccine, NovaDigm
US-based biopharmaceutical firm Tracon Pharmaceuticals has started dosing in a Phase Ib clinical of TRC105 for the treatment of patients with metastatic renal cell carcinoma. The trial evaluates the combination of TRC105 and a standard ...
Tags: Tracon, Carcinoma Drug
arGEN-X, a clinical stage human monoclonal antibody therapeutics company, cin its SIMPLE Antibody research program collaboration with Shire Pharmaceuticals' Human Genetic Therapies division. The milestone, which was the first ...
The US Food and Drug Administration (FDA) has approved breakthrough therapy designation for Danish biotechnology company Genmab and British pharmaceutical company GlaxoSmithKline’s (GSK) Arzerra (ofatumumab) in combination with ...
Tags: therapy designation, Medicine
NovelMed Therapeutics has received a combined $1.43m small business innovation research (SBIR) grant from the National Institutes of Health (NIH) to further develop its anti-complement antibody for orphan disease. The company will use the ...
Therapeutic antibodies developer AnaptysBio has expanded its proprietary immunotherapy antibody portfolio to add multiple new combination therapies. The company developed a proprietary anti-PD-1 antibody, called ANB011, with key ...
Tags: AnaptysBio, Antibody Portfolio
Cell Signaling Technology has presented a specific HER3 rabbit monoclonal antibody (mAb) for researchers studying HER2-mediated breast, lung and ovarian tumors. The company has introduced this product with the recent need for HER3 in HER2 ...
Biotechnology company Bharat Biotech has introduced world's first clinically proven typhoid conjugate vaccine, Typbar-TCV, to protect infants aged six months and more and adults from typhoid fever caused by Salmonella typhi. Commercial ...
Tags: Bharat Biotech, Vaccine
Clinical-stage company OncoMed Pharmaceuticals has announced the issuance of US patent for methods of treating cancer with its antibody vantictumab (OMP-18R5) through 2029. Targeting and inhibiting the Wnt pathway, Vantictumab was ...
Tags: Vantictumab, OncoMed
Adimab signed a multi-target discovery agreement with Celgene Corporation, pursuant to which, Adimab will use its proprietary discovery and optimization platform to generate fully human antibodies against multiple targets. Under the terms ...
Tags: Adimab, Drug Discovery
Adimab and Innovent have collaborated to discover, develop and commercialise an antibody-based therapeutic, using Adimab antibody discovery and optimization platform, against a selected specific target. All initial product development ...
Tags: Adimab, Antibody-Based Therapeutic
Biotechnology company Biocon has launched the first anti-CD6 monoclonal antibody, alzumab (Itolizumab), to treat patients with chronic plaque psoriasis in India. Indicated for the treatment of moderate-to-severe psoriasis, Alzumab is ...
The US Food and Drug Administration (FDA) has approved Alere's pre-market application (PMA) for the commercialization of Alere Determine HIV 1/2 Ag/Ab Combo in the country. The FDA approval allows the marketing of Alere Determine HIV 1/2 ...
Tags: Alere Determine, Medicine